SLU-PP-332

Description

SLU-PP-332

SLU-PP-332 is a novel, small-molecule dual estrogen-related receptor (ERR) alpha and gamma ($\text{ERR}\alpha/\gamma$) inverse agonist. Developed to investigate the molecular architecture of skeletal muscle remodeling and endurance adaptation, this investigational compound serves as an exercise mimetic in research models. By activating nuclear receptor pathways typically triggered by physical exertion, it allows investigators to study metabolic optimization and fiber-type switching independent of mechanical workload.

How It Works

• ERR Path Activation: Functions as a potent agonist of $\text{ERR}\alpha$ and $\text{ERR}\gamma$, nuclear receptors that regulate the transcription of genes responsible for mitochondrial biogenesis and oxidative metabolism.

• Mitochondrial Biogenesis Induction: Upregulates key downstream targets, including peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1$\alpha$), driving the proliferation and structural complexity of cellular mitochondria.

• Skeletal Muscle Remodeling: Promotes a phenotypic shift in skeletal muscle tissue from glycolytic (fast-twitch) to oxidative (slow-twitch) fibers, enhancing baseline fatigue resistance at the cellular level.

Research & Scientific Interest

• Exercise Mimetic & Performance Models: Widely studied to observe systemic adaptations analogous to endurance training, particularly variations in physical performance and oxygen consumption ($VO_2$ kinetics).

• Mitochondrial Oxidative Capacity: Utilized to evaluate changes in fatty-acid oxidation rates, cellular respiration efficiency, and overall ATP yield within muscular tissue.

• Metabolic Syndrome & Obesity Research: Investigated for its potential to alter systemic energy expenditure, mitigate diet-induced lipid accumulation, and improve glucose homeostasis in metabolic dysfunction models.

• Muscle Atrophy Countermeasures: Serves as an analytical tool for evaluating structural preservation in models simulating prolonged immobilization, spaceflight-induced muscle wasting, or age-related sarcopenia.

Pharmacology

SLU-PP-332 demonstrates high specificity for the estrogen-related receptor family without cross-reacting with classical estrogen receptors ($\text{ER}\alpha$ or $\text{ER}\beta$). As an investigational research compound, it is typically prepared in specialized vehicle solutions optimized for systemic administration in in-vivo models. The compound possesses a distinct pharmacokinetic profile that ensures reliable nuclear receptor binding, permitting precise quantification of target gene expression, structural fiber transitions, and tissue-specific lipid clearance rates.

Bottom Line

SLU-PP-332 is a pioneering $\text{ERR}\alpha/\gamma$ agonist that provides an unprecedented mechanism for analyzing mitochondrial up-regulation and structural muscle adaptation without physical exercise. Its high receptor specificity makes it a primary asset for cutting-edge metabolic, endurance, and sarcopenia research. Research Use Only: SLU-PP-332 is supplied strictly for laboratory and research purposes. It is not approved for human consumption, medical, or veterinary use.